GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Staidson (Beijing) Biopharmaceuticals Co Ltd (SZSE:300204) » Definitions » Scaled Net Operating Assets

Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) Scaled Net Operating Assets : 0.70 (As of Dec. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Staidson (Beijing) Biopharmaceuticals Co Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Staidson (Beijing) Biopharmaceuticals Co's operating assets for the quarter that ended in Dec. 2024 was ¥1,095.7 Mil. Staidson (Beijing) Biopharmaceuticals Co's operating liabilities for the quarter that ended in Dec. 2024 was ¥202.7 Mil. Staidson (Beijing) Biopharmaceuticals Co's Total Assets for the quarter that ended in Sep. 2024 was ¥1,284.1 Mil. Therefore, Staidson (Beijing) Biopharmaceuticals Co's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2024 was 0.70.


Staidson (Beijing) Biopharmaceuticals Co Scaled Net Operating Assets Historical Data

The historical data trend for Staidson (Beijing) Biopharmaceuticals Co's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Staidson (Beijing) Biopharmaceuticals Co Scaled Net Operating Assets Chart

Staidson (Beijing) Biopharmaceuticals Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.56 0.59 0.60 0.58 0.67

Staidson (Beijing) Biopharmaceuticals Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.65 0.75 0.78 0.76 0.70

Competitive Comparison of Staidson (Beijing) Biopharmaceuticals Co's Scaled Net Operating Assets

For the Biotechnology subindustry, Staidson (Beijing) Biopharmaceuticals Co's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Staidson (Beijing) Biopharmaceuticals Co's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Staidson (Beijing) Biopharmaceuticals Co's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Staidson (Beijing) Biopharmaceuticals Co's Scaled Net Operating Assets falls into.


;
;

Staidson (Beijing) Biopharmaceuticals Co Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Staidson (Beijing) Biopharmaceuticals Co's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2024 )
=(Operating Assets (A: Dec. 2024 )-Operating Liabilities (A: Dec. 2024 ))/Total Assets (A: Dec. 2023 )
=(1095.697-202.703)/1332.22
=0.67

where

Operating Assets(A: Dec. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=1149.608 - 53.911
=1095.697

Operating Liabilities(A: Dec. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=232.846 - 0.06 - 30.083
=202.703

Staidson (Beijing) Biopharmaceuticals Co's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2024 )
=(Operating Assets (Q: Dec. 2024 )-Operating Liabilities (Q: Dec. 2024 ))/Total Assets (Q: Sep. 2024 )
=(1095.697-202.703)/1284.119
=0.70

where

Operating Assets(Q: Dec. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=1149.608 - 53.911
=1095.697

Operating Liabilities(Q: Dec. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=232.846 - 0.06 - 30.083
=202.703

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Staidson (Beijing) Biopharmaceuticals Co Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Staidson (Beijing) Biopharmaceuticals Co's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Staidson (Beijing) Biopharmaceuticals Co Business Description

Traded in Other Exchanges
N/A
Address
Rongjing Dong Street, No 5 Beijing Economic and Technological Development Zone, Beijing, CHN, 100176
Staidson (Beijing) Biopharmaceuticals Co Ltd is a pharmaceutical company mainly engaged in the research, development, production, and sale of biological products in China. Its products include mouse nerve growth factor injection, intravenous compound polyethylene glycol electrolyte powder solution, gliclazide, nabumetone, and aspirin.
Executives
Zhang Hong Shan Supervisors
Zheng Hong Supervisors
Cheng Jiang Hong Executives
Feng Yu Jing Executives
Ma Li Na Secretary, Director
Zhou Zhi Wen Director
Wang Huan Securities Affairs Representative
Zhang Rong Qin Executives
Xu Jiang Ping Executives
Cao Hai Yan Supervisors
Sun Yan Fang Executives
Jiang Li Xin Director
Gu Jian Ping Director
Xu Xiang Qing Supervisors
Gu Zhen Qi Director

Staidson (Beijing) Biopharmaceuticals Co Headlines

No Headlines